The survey, commissioned by the Alliance for Aging Research and sponsored by the two drugmakers, spanned 1,000 U.S. adults and 1,000 unpaid or family Alzheimer’s caregivers.
Senju launches first-in-class dry eye disease drug in Japan
Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the

